Does  ||| S:0 E:5 ||| VBZ
FVIII-activity  ||| S:5 E:20 ||| JJ
increase  ||| S:20 E:29 ||| NN
with  ||| S:29 E:34 ||| IN
age  ||| S:34 E:38 ||| NN
in  ||| S:38 E:41 ||| IN
patients  ||| S:41 E:50 ||| NNS
with  ||| S:50 E:55 ||| IN
haemophilia  ||| S:55 E:67 ||| JJ
A  ||| S:67 E:69 ||| NN
and  ||| S:69 E:73 ||| CC
carriers  ||| S:73 E:82 ||| NNS
of  ||| S:82 E:85 ||| IN
haemophilia  ||| S:85 E:97 ||| JJ
A ||| S:97 E:98 ||| NN
?  ||| S:98 E:100 ||| .
The  ||| S:100 E:104 ||| DT
retrospective  ||| S:104 E:118 ||| JJ
cohort  ||| S:118 E:125 ||| JJ
study  ||| S:125 E:131 ||| NN
surveys  ||| S:131 E:139 ||| NNS
the  ||| S:139 E:143 ||| DT
influence  ||| S:143 E:153 ||| NN
of  ||| S:153 E:156 ||| IN
age ||| S:156 E:159 ||| NN
,  ||| S:159 E:161 ||| ,
co-morbidity  ||| S:161 E:174 ||| JJ
and  ||| S:174 E:178 ||| CC
laboratory  ||| S:178 E:189 ||| NN
values  ||| S:189 E:196 ||| NNS
on  ||| S:196 E:199 ||| IN
FVIII-activity  ||| S:199 E:214 ||| NNP
( ||| S:214 E:215 ||| -LRB-
FVIII ||| S:215 E:220 ||| NNP
: ||| S:220 E:221 ||| :
C ||| S:221 E:222 ||| NNP
)  ||| S:222 E:224 ||| -RRB-
in  ||| S:224 E:227 ||| IN
patients  ||| S:227 E:236 ||| NNS
with  ||| S:236 E:241 ||| IN
haemophilia  ||| S:241 E:253 ||| JJ
A  ||| S:253 E:255 ||| NN
with  ||| S:255 E:260 ||| IN
( ||| S:260 E:261 ||| -LRB-
mild  ||| S:261 E:266 ||| JJ
n  ||| S:266 E:268 ||| NN
=  ||| S:268 E:270 ||| SYM
48 ||| S:270 E:272 ||| CD
,  ||| S:272 E:274 ||| ,
moderate  ||| S:274 E:283 ||| JJ
n  ||| S:283 E:285 ||| NN
=  ||| S:285 E:287 ||| SYM
10 ||| S:287 E:289 ||| CD
,  ||| S:289 E:291 ||| ,
severe  ||| S:291 E:298 ||| JJ
n  ||| S:298 E:300 ||| NN
=  ||| S:300 E:302 ||| SYM
7  ||| S:302 E:304 ||| CD
and  ||| S:304 E:308 ||| CC
carriers  ||| S:308 E:317 ||| NNS
n  ||| S:317 E:319 ||| VBG
=  ||| S:319 E:321 ||| SYM
23 ||| S:321 E:323 ||| CD
) ||| S:323 E:324 ||| -RRB-
.  ||| S:324 E:326 ||| .
Median  ||| S:326 E:333 ||| JJ
observation  ||| S:333 E:345 ||| NN
was  ||| S:345 E:349 ||| VBD
19  ||| S:349 E:352 ||| CD
years  ||| S:352 E:358 ||| NNS
for  ||| S:358 E:362 ||| IN
patients  ||| S:362 E:371 ||| NNS
with  ||| S:371 E:376 ||| IN
haemophilia  ||| S:376 E:388 ||| JJ
A  ||| S:388 E:390 ||| NN
and  ||| S:390 E:394 ||| CC
9 ||| S:394 E:395 ||| CD
, ||| S:395 E:396 ||| ,
5  ||| S:396 E:398 ||| CD
years  ||| S:398 E:404 ||| NNS
for  ||| S:404 E:408 ||| IN
carriers ||| S:408 E:416 ||| NNS
.  ||| S:416 E:418 ||| .
FVIII ||| S:418 E:423 ||| NNP
: ||| S:423 E:424 ||| :
C  ||| S:424 E:426 ||| NNP
levels  ||| S:426 E:433 ||| NNS
collected  ||| S:433 E:443 ||| VBN
from  ||| S:443 E:448 ||| IN
patients  ||| S:448 E:457 ||| NNS
with  ||| S:457 E:462 ||| IN
mild  ||| S:462 E:467 ||| JJ
haemophilia  ||| S:467 E:479 ||| NNS
A  ||| S:479 E:481 ||| DT
displayed  ||| S:481 E:491 ||| VBN
a  ||| S:491 E:493 ||| DT
significant  ||| S:493 E:505 ||| JJ
median  ||| S:505 E:512 ||| JJ
increase  ||| S:512 E:521 ||| NN
of  ||| S:521 E:524 ||| IN
6.5 ||| S:524 E:527 ||| CD
%  ||| S:527 E:529 ||| NN
with  ||| S:529 E:534 ||| IN
proceeding  ||| S:534 E:545 ||| VBG
age  ||| S:545 E:549 ||| NN
( ||| S:549 E:550 ||| -LRB-
p  ||| S:550 E:552 ||| CD
=  ||| S:552 E:554 ||| SYM
0.0013 ||| S:554 E:560 ||| CD
) ||| S:560 E:561 ||| -RRB-
.  ||| S:561 E:563 ||| .
Patients  ||| S:563 E:572 ||| NNS
with  ||| S:572 E:577 ||| IN
moderate  ||| S:577 E:586 ||| JJ
haemophilia  ||| S:586 E:598 ||| NNS
A  ||| S:598 E:600 ||| DT
( ||| S:600 E:601 ||| -LRB-
and  ||| S:601 E:605 ||| CC
carriers  ||| S:605 E:614 ||| NNS
of  ||| S:614 E:617 ||| IN
haemophilia  ||| S:617 E:629 ||| JJ
A ||| S:629 E:630 ||| NNP
)  ||| S:630 E:632 ||| -RRB-
showed  ||| S:632 E:639 ||| VBD
a  ||| S:639 E:641 ||| DT
non  ||| S:641 E:645 ||| JJ
significant  ||| S:645 E:657 ||| JJ
median  ||| S:657 E:664 ||| JJ
increase  ||| S:664 E:673 ||| NN
of  ||| S:673 E:676 ||| IN
1.05 ||| S:676 E:680 ||| CD
%  ||| S:680 E:682 ||| NN
( ||| S:682 E:683 ||| -LRB-
carriers  ||| S:683 E:692 ||| CD
8 ||| S:692 E:693 ||| CD
% ||| S:693 E:694 ||| NN
) ||| S:694 E:695 ||| -RRB-
.  ||| S:695 E:697 ||| .
Eight  ||| S:697 E:703 ||| CD
patients  ||| S:703 E:712 ||| NNS
showed  ||| S:712 E:719 ||| VBD
FVIII ||| S:719 E:724 ||| NNP
: ||| S:724 E:725 ||| :
C  ||| S:725 E:727 ||| NNP
levels  ||| S:727 E:734 ||| NNS
at  ||| S:734 E:737 ||| IN
last  ||| S:737 E:742 ||| JJ
blood  ||| S:742 E:748 ||| NN
withdrawal  ||| S:748 E:759 ||| NN
that  ||| S:759 E:764 ||| WDT
indicated  ||| S:764 E:774 ||| VBD
a  ||| S:774 E:776 ||| DT
change  ||| S:776 E:783 ||| NN
of  ||| S:783 E:786 ||| IN
severity  ||| S:786 E:795 ||| NN
from  ||| S:795 E:800 ||| IN
moderate  ||| S:800 E:809 ||| JJ
to  ||| S:809 E:812 ||| TO
mild  ||| S:812 E:817 ||| JJ
haemophilia  ||| S:817 E:829 ||| JJ
A.  ||| S:829 E:832 ||| NN
A  ||| S:832 E:834 ||| DT
significant  ||| S:834 E:846 ||| JJ
correlation  ||| S:846 E:858 ||| NN
was  ||| S:858 E:862 ||| VBD
found  ||| S:862 E:868 ||| VBN
between  ||| S:868 E:876 ||| IN
FVIII ||| S:876 E:881 ||| NNP
: ||| S:881 E:882 ||| :
C  ||| S:882 E:884 ||| NNP
and  ||| S:884 E:888 ||| CC
VWF ||| S:888 E:891 ||| NNP
: ||| S:891 E:892 ||| :
RCo  ||| S:892 E:896 ||| NNP
( ||| S:896 E:897 ||| -LRB-
p  ||| S:897 E:899 ||| CD
=  ||| S:899 E:901 ||| SYM
0.0203 ||| S:901 E:907 ||| CD
)  ||| S:907 E:909 ||| -RRB-
and  ||| S:909 E:913 ||| CC
AFP  ||| S:913 E:917 ||| NNP
( ||| S:917 E:918 ||| -LRB-
p  ||| S:918 E:920 ||| FW
< ||| S:920 E:922 ||| SYM
0.0005 ||| S:922 E:928 ||| FW
) ||| S:928 E:929 ||| -RRB-
.  ||| S:929 E:931 ||| .
The  ||| S:931 E:935 ||| DT
correlation  ||| S:935 E:947 ||| NN
between  ||| S:947 E:955 ||| IN
FVIII ||| S:955 E:960 ||| NNP
: ||| S:960 E:961 ||| :
C  ||| S:961 E:963 ||| NNP
and  ||| S:963 E:967 ||| CC
triglycerides  ||| S:967 E:981 ||| NNS
and  ||| S:981 E:985 ||| CC
LDH  ||| S:985 E:989 ||| NNP
was  ||| S:989 E:993 ||| VBD
significant  ||| S:993 E:1005 ||| JJ
negative  ||| S:1005 E:1014 ||| JJ
( ||| S:1014 E:1015 ||| -LRB-
p  ||| S:1015 E:1017 ||| FW
< ||| S:1017 E:1019 ||| SYM
0.0005 ||| S:1019 E:1025 ||| FW
) ||| S:1025 E:1026 ||| -RRB-
.  ||| S:1026 E:1028 ||| .
No  ||| S:1028 E:1031 ||| DT
significant  ||| S:1031 E:1043 ||| JJ
correlation  ||| S:1043 E:1055 ||| NN
could  ||| S:1055 E:1061 ||| MD
be  ||| S:1061 E:1064 ||| VB
found  ||| S:1064 E:1070 ||| VBN
for  ||| S:1070 E:1074 ||| IN
FVIII ||| S:1074 E:1079 ||| NNP
: ||| S:1079 E:1080 ||| :
C  ||| S:1080 E:1082 ||| NNP
and  ||| S:1082 E:1086 ||| CC
co-morbidity ||| S:1086 E:1098 ||| JJ
,  ||| S:1098 E:1100 ||| ,
fibrinogen ||| S:1100 E:1110 ||| NN
,  ||| S:1110 E:1112 ||| ,
cholesterol  ||| S:1112 E:1124 ||| NN
and  ||| S:1124 E:1128 ||| CC
VWF ||| S:1128 E:1131 ||| NNP
: ||| S:1131 E:1132 ||| :
Ag ||| S:1132 E:1134 ||| NNP
.  ||| S:1134 E:1136 ||| .
